What eli lilly canada does

Eli Lilly Canada Inc. is the Canadian operating subsidiary of Eli Lilly and Company (NYSE: LLY), headquartered in Toronto. The entity is responsible for distributing Lilly's prescription pharmaceutical products to Canadian patients and providing clinical information resources to Canadian Healthcare Professionals. Its core commercial interface is a two-portal model: a DIN-gated patient portal at ca.lilly.com that requires a valid Drug Identification Number to access product information, and an authenticated Healthcare Professional portal at account.lilly.com for clinical and product resources. A Customer Response Centre (1-888-545-5972) provides direct phone support for both audiences.

The subsidiary's business model is structurally simple: it monetizes indirectly as the Canadian distribution arm of the parent's patented pharmaceutical portfolio, generating revenue through prescription sales channeled via Canadian pharmacies and healthcare providers. Pricing is not publicly disclosed; product information is gated behind DIN verification, which functions both as a regulatory compliance mechanism (Health Canada) and a lead-qualification filter. Customer segments consist of prescribed patients (primary) and Healthcare Professionals (secondary), with no named enterprise anchors disclosed and no headcount figure provided.

Eli Lilly Canada currently faces a Canada Revenue Agency tax audit and lawsuit related to its 2020 filings and transfer pricing with Irish affiliates, which introduces regulatory and financial uncertainty. No funding rounds, M&A activity, leadership changes, or direct AI/technology investments are disclosed at the subsidiary level. Strategic positioning is fully derivative of the parent's global pipeline, including GLP-1 franchises and the experimental obesity candidate retatrutide.

Name

eli lilly canada

Legal name

Eli Lilly Canada Inc

Website

https://lillypro.ca

Company type

Public

Operating status

Operating

Short description

Eli Lilly Canada Inc. is the Toronto-based Canadian subsidiary of Eli Lilly and Company (NYSE: LLY), distributing the parent's prescription pharmaceutical products to Canadian patients with valid DINs and providing clinical resources to Healthcare Professionals via dedicated portals and a Customer Response Centre.

Ownership category

akta.pro rank

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Compounding Ingredient & API Distributors (Pharma Supply) (HLAIAJAO)

Keywords

• Prescription pharmaceuticals
• Patient support services
• Healthcare professional portal
• Clinical information access
• DIN verification

Headquarters

HQ city

Toronto

HQ country

Canada

HQ region

North America

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Others

Distribution channels1 record

Marketing channels2 records

Core offering

Eli Lilly Canada Inc provides prescription pharmaceutical products to Canadian patients who have a valid Drug Identification Number (DIN), and clinical/product information resources to Canadian Healthcare Professionals through a dedicated authenticated portal. The organization supports patients and HCPs via a Customer Response Centre (1-888-545-5972) and a tiered website (ca.lilly.com) that gates content by DIN verification or HCP sign-in.

Product overview

Eli Lilly Canada operates a pharmaceutical products information portal for patients and healthcare professionals. The company offers a patient-facing website that requires a valid DIN (Drug Identification Number) for access, along with a separate Healthcare Professional portal. The company provides prescription medications and maintains a Customer Response Centre at 1-888-545-5972. Specific pharmaceutical product names and details are accessible through authenticated access to these portals.

Differentiator

Problem solved

Functional benefit

Segments2 records

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves4 records

Expansion highlights3 records

Direct peers

• Pfizer Canada: Pfizer Canada ULC is the Canadian subsidiary of Pfizer Inc., a global pharmaceutical leader. Direct comparable to Eli Lilly Canada as both distribute the parent's prescription pharmaceutical portfolio to Canadian patients and HCPs, operate similar regulatory and patient-support models, and compete in identical therapeutic categories.
• Roche Canada: Hoffmann-La Roche Limited (Roche Canada) is the Canadian subsidiary of F. Hoffmann-La Roche. Highly comparable to Eli Lilly Canada: distributes the parent's prescription pharmaceutical products in Canada, supports patients and HCPs, and operates across multiple therapeutic areas including oncology, the parent's flagship franchise.
• Novartis Pharmaceuticals Canada: Novartis Pharmaceuticals Canada Inc. is the Canadian subsidiary of Novartis AG. Comparable to Eli Lilly Canada as a major Swiss pharma subsidiary distributing prescription products across cardiovascular, oncology, immunology, and neuroscience in Canada, with similar HCP engagement infrastructure.
• Merck Canada: Merck Canada Inc., the Canadian subsidiary of Merck & Co. (known as MSD outside North America), directly parallels Eli Lilly Canada. Both distribute the parent's prescription drug portfolio in Canada, serve patients and HCPs, and compete in overlapping therapeutic areas including oncology, vaccines, and diabetes.
• AstraZeneca Canada: AstraZeneca Canada Inc. is the Canadian subsidiary of AstraZeneca PLC. Direct comparable to Eli Lilly Canada: distributes prescription pharmaceuticals across oncology, cardiovascular, renal-metabolic (including diabetes), and respiratory in Canada, with parallel patient and HCP engagement models.
• GSK Canada: GlaxoSmithKline Inc. (GSK Canada) is the Canadian subsidiary of GSK plc. Comparable to Eli Lilly Canada as a major UK pharma subsidiary distributing prescription pharmaceuticals and vaccines in Canada, with similar regulatory positioning and HCP-facing infrastructure.
• Sanofi Canada: Sanofi-Aventis Canada Inc. is the Canadian subsidiary of Sanofi S.A. Direct comparable to Eli Lilly Canada as a global pharma subsidiary distributing prescription pharmaceuticals (notably in diabetes, where both companies compete via GLP-1 and insulin franchises) and operating patient/HCP support channels in Canada.
• AbbVie Canada: AbbVie Corporation is the Canadian subsidiary of AbbVie Inc. Highly comparable to Eli Lilly Canada: distributes a diversified prescription pharmaceutical portfolio in Canada, operates similar patient and HCP engagement models, and competes across immunology, oncology, and neuroscience.
• Bristol Myers Squibb Canada: Bristol-Myers Squibb Canada Co. is the Canadian subsidiary of Bristol Myers Squibb Company. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, hematology, immunology, and cardiovascular disease in Canada.
• Johnson & Johnson Innovative Medicine Canada: Janssen Inc. (Johnson & Johnson Innovative Medicine) is the Canadian pharmaceutical subsidiary of Johnson & Johnson. Comparable to Eli Lilly Canada as a major US pharma subsidiary distributing prescription pharmaceuticals across oncology, immunology, neuroscience, and pulmonary hypertension in Canada.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights5 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about eli lilly canada